In summary, the generation of mice deficient in fibulin-2 and ADAMTS-12 contributed to the in vivo validation that the interaction between these two proteins has an antitumor role in lung cancer and has an effect in modulating the immune response after lung injury. This evidence concerns the gene FBLN2 and lung carcinoma.